RVNC - Revance Therapeutics, Inc.

0   0%

Share volume: 0
Last Updated:
Pharmaceutical Products/Pharmaceutical Preparations: 0.00%

PREVIOUS CLOSE
CHG
CHG%
N/A
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
8%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 20%
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
N/A
P/E Ratio 
N/A
DAY RANGE
N/A - N/A
EPS 
N/A
52 WEEK RANGE
N/A - N/A
52 WEEK CHANGE
N/A
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-15-2025
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO: Mark J. Foley
Region: US
Website: revance.com
Employees: 500
IPO year: 2014
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Revance Therapeutics, Inc. engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia.

Recent news
loading